Achieving sufficient delivery across the blood–brain barrier is a key challenge in the
development of drugs to treat central nervous system (CNS) disorders. This is particularly …

The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …

Current treatments for Alzheimer's disease (AD) that focus on inhibition of Aβ aggregation
failed to show effectiveness in people who already had Alzheimer's symptoms. Strategies …

Brain delivery is one of the major challenges in drug development because of the high
number of patients suffering from neural diseases and the low efficiency of the treatments …

Nearly one in six people worldwide suffer from disorders of the central nervous system
(CNS). There is an urgent need for effective strategies to improve the success rates in CNS …

Peptide-based strategies have received an enormous amount of attention because of their
specificity and applicability. Their specificity and tumor-targeting ability are applied to …

Alzheimer's disease (AD) is an incurable and fatal progressive neurodegenerative disorder
associated with memory and cognition impairment. AD is one of the top medical care …

Chemotherapy outcomes for the treatment of glioma remain unsatisfied due to the inefficient
drug transport across BBB/BBTB and poor drug accumulation in the tumor site. Nanocarriers …

Neurodegenerative diseases and disorders seriously impact memory and cognition and can
become life-threatening. Current medical techniques attempt to combat these detrimental …

Chemotherapy for brain glioma has been of limited benefit due to the inability of drugs to
penetrate the blood–brain barrier (BBB) and non-selective drug accumulation in the entire …